CliffBio
biologic

Ervebo

Ebola Zaire Vaccine, Live

Loss of exclusivityDecember 2031FDA regulatory exclusivity expiry
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameErvebo
Active ingredientEbola Zaire Vaccine, Live
Strength1ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalDecember 2019
Marketing statusRx

More from Merck Sharp & Dohme LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Ervebo patent cliff — loss of exclusivity December 2031 | CliffBio